First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
28
08
2020
accepted:
13
11
2020
pubmed:
23
2
2021
medline:
15
5
2021
entrez:
22
2
2021
Statut:
ppublish
Résumé
Anti-IL-17A IgG/κ monoclonal antibody CJM112 binds both IL-17A and IL-17AF. The purpose of this First-in-Human study was to assess CJM112 effects on safety and efficacy in patients with moderate to severe plaque psoriasis. This study had two parts: single ascending doses of 5-450 mg subcutaneous (s.c.) CJM112 (SAD) and multi-dose parallel groups of CJM112 15 mg, 50 mg and 150 mg s.c. low frequency or high frequency (MD). SAD/MD were double-blind, randomized and placebo-controlled; MD also included a secukinumab 150 mg s.c. arm as an active comparator. Patients 18-65 years with moderate to severe psoriasis were included in this study. The efficacy outcome was the change in Psoriasis Area Severity Index (PASI) from baseline to Week 4 in the SAD part of the study, and from baseline to Week 12 in the MD part. 96 patients were enrolled in this study (SAD, n = 42; MD, n = 54). In SAD, CJM112 doses from 15 mg and above demonstrated higher PASI responses compared with placebo at Week 12. CJM112 450 mg did not add further efficacy, but efficacy duration was prolonged compared with CJM112 150 mg. CJM112 MD resulted in a dose-dependent decrease in PASI over time to Week 12. CJM112 150 mg high frequency did not exceed the effect of CJM112 150 mg low frequency and had similar efficacy to secukinumab 150 mg. The safety profile of CJM112 was as expected for an antibody targeting IL-17A/IL-17AF. CJM112 had clinical efficacy in moderate to severe psoriasis and was generally safe and well tolerated in the doses tested. Additional neutralization of IL-17AF did not translate to increased clinical efficacy compared with secukinumab.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Anti-IL-17A IgG/κ monoclonal antibody CJM112 binds both IL-17A and IL-17AF. The purpose of this First-in-Human study was to assess CJM112 effects on safety and efficacy in patients with moderate to severe plaque psoriasis.
METHODS
METHODS
This study had two parts: single ascending doses of 5-450 mg subcutaneous (s.c.) CJM112 (SAD) and multi-dose parallel groups of CJM112 15 mg, 50 mg and 150 mg s.c. low frequency or high frequency (MD). SAD/MD were double-blind, randomized and placebo-controlled; MD also included a secukinumab 150 mg s.c. arm as an active comparator. Patients 18-65 years with moderate to severe psoriasis were included in this study. The efficacy outcome was the change in Psoriasis Area Severity Index (PASI) from baseline to Week 4 in the SAD part of the study, and from baseline to Week 12 in the MD part.
RESULTS
RESULTS
96 patients were enrolled in this study (SAD, n = 42; MD, n = 54). In SAD, CJM112 doses from 15 mg and above demonstrated higher PASI responses compared with placebo at Week 12. CJM112 450 mg did not add further efficacy, but efficacy duration was prolonged compared with CJM112 150 mg. CJM112 MD resulted in a dose-dependent decrease in PASI over time to Week 12. CJM112 150 mg high frequency did not exceed the effect of CJM112 150 mg low frequency and had similar efficacy to secukinumab 150 mg. The safety profile of CJM112 was as expected for an antibody targeting IL-17A/IL-17AF.
CONCLUSIONS
CONCLUSIONS
CJM112 had clinical efficacy in moderate to severe psoriasis and was generally safe and well tolerated in the doses tested. Additional neutralization of IL-17AF did not translate to increased clinical efficacy compared with secukinumab.
Identifiants
pubmed: 33617042
doi: 10.1111/jdv.17071
pmc: PMC8246720
doi:
Substances chimiques
Antibodies, Monoclonal
0
Interleukin-17
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143-1151Subventions
Organisme : Novartis Pharma AG
Informations de copyright
© 2020 Novartis Pharma AG. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
J Allergy Clin Immunol. 2017 Mar;139(3):923-932.e8
pubmed: 27502297
G Ital Dermatol Venereol. 2016 Dec;151(6):663-677
pubmed: 27589483
AAPS J. 2017 Jul;19(4):1218-1222
pubmed: 28534291
Br J Dermatol. 2016 Aug;175(2):273-86
pubmed: 26914406
Clin Dermatol. 2018 Jan - Feb;36(1):21-28
pubmed: 29241748
J Invest Dermatol. 2015 Apr;135(4):984-991
pubmed: 25521458
Br J Dermatol. 2009 Feb;160(2):319-24
pubmed: 19016708
Br J Dermatol. 1998 Nov;139(5):846-50
pubmed: 9892952
J Eur Acad Dermatol Venereol. 2010 May;24(5):548-54
pubmed: 19874432
Nat Immunol. 2005 Nov;6(11):1123-32
pubmed: 16200070
Immunity. 2009 Jan 16;30(1):108-19
pubmed: 19144317
J Clin Pharmacol. 2017 Jul;57(7):876-885
pubmed: 28273356
Ann Rheum Dis. 2020 May;79(5):595-604
pubmed: 32253184
J Immunol. 2018 Sep 15;201(6):1605-1613
pubmed: 30181299
J Invest Dermatol. 2009 Sep;129(9):2175-83
pubmed: 19295614
Nat Rev Immunol. 2009 Aug;9(8):556-67
pubmed: 19575028
N Engl J Med. 2015 Oct;373(14):1318-28
pubmed: 26422722
Cold Spring Harb Perspect Med. 2014 Aug 01;4(8):
pubmed: 25085957
J Exp Med. 2008 May 12;205(5):1063-75
pubmed: 18411338
Front Immunol. 2018 Apr 05;9:579
pubmed: 29675020
J Inflamm Res. 2016 Apr 19;9:39-50
pubmed: 27143947